177 related articles for article (PubMed ID: 29553945)
21. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
22. Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation.
Qu M; Li J; Yuan L
Bioengineered; 2021 Dec; 12(2):12940-12953. PubMed ID: 34847838
[TBL] [Abstract][Full Text] [Related]
23. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
24. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
25. Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine.
Zhang FY; Hu Y; Que ZY; Wang P; Liu YH; Wang ZH; Xue YX
Int J Mol Sci; 2015 Oct; 16(10):23823-48. PubMed ID: 26473829
[TBL] [Abstract][Full Text] [Related]
26. Actein antagonizes colorectal cancer through blocking PI3K/Akt pathways by downregulating IMPDH2.
Yan L; Wang D; Liu X; Gu C; Gao S
Anticancer Drugs; 2021 Sep; 32(8):864-874. PubMed ID: 33929996
[TBL] [Abstract][Full Text] [Related]
27. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells.
Li X; Tian R; Liu L; Wang L; He D; Cao K; Ma JK; Huang C
J Int Med Res; 2020 Aug; 48(8):300060520946169. PubMed ID: 32787737
[TBL] [Abstract][Full Text] [Related]
28. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
29. Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA‑21 and the suppression of the PI3K/Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma.
Zhang H; Li J; Li G; Wang S
Mol Med Rep; 2016 Dec; 14(6):5363-5368. PubMed ID: 27840916
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway.
Lv X; Li CY; Han P; Xu XY
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2321-2327. PubMed ID: 29762835
[TBL] [Abstract][Full Text] [Related]
32. Promethazine inhibits proliferation and promotes apoptosis in colorectal cancer cells by suppressing the PI3K/AKT pathway.
Tan X; Gong L; Li X; Zhang X; Sun J; Luo X; Wang Q; Chen J; Xie L; Han S
Biomed Pharmacother; 2021 Nov; 143():112174. PubMed ID: 34560542
[TBL] [Abstract][Full Text] [Related]
33. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
34.
Qian Y; Yan Y; Lu H; Zhou T; Lv M; Fang C; Hou J; Li W; Chen X; Sun H; Li Y; Wang Z; Zhao N; Gu Y; Ding Y; Liu Y
Anticancer Agents Med Chem; 2019; 19(14):1754-1761. PubMed ID: 31364518
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of GRHL2 inhibited proliferation and induced apoptosis of colorectal cancer by suppressing the PI3K/Akt pathway.
Hu F; He Z; Sun C; Rong D
Gene; 2019 Jun; 700():96-104. PubMed ID: 30917932
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
37. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-κB signaling pathway.
Sha M; Ye J; Zhang LX; Luan ZY; Chen YB; Huang JX
Pharmacology; 2014; 93(1-2):39-46. PubMed ID: 24434352
[TBL] [Abstract][Full Text] [Related]
38. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
39. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
40. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]